Published • loading... • Updated
Akeso's Gumokimab (AK111, Anti-IL-17) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis, Bolstering Its Autoimmune Disease Portfolio
- The National Medical Products Administration of China approved Akeso's gumokimab for treating adult patients with moderate-to-severe plaque psoriasis.
- The approval was based on one pivotal Phase III clinical trial and three supportive clinical studies.
- Clinical studies showed gumokimab has rapid efficacy, durable complete skin clearance, and a favorable safety and dosing profile.
- A supplemental application for gumokimab to treat active ankylosing spondylitis is under review by the National Medical Products Administration's Center for Drug Evaluation.
Insights by Ground AI
36 Articles
36 Articles
LoudounTimes.com+34 Reposted by 34 other sources
Akeso's Gumokimab (AK111, Anti-IL-17) Approved by NMPA for Moderate-to-Severe Plaque Psoriasis, Bolstering Its Autoimmune Disease Portfolio
HONG KONG, June 11, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) today announced that the National Medical Products Administration (NMPA) of China has approved gumokimab (AK111), the company's internally-developed anti-IL-17 monoclonal antibody, for the treatment of adult patients with moderate-to-severe plaque…
China’s NMPA approves Akeso’s gumokimab for plaque psoriasis
The approval is based on data from one pivotal Phase III trial (AK111-301) and three additional supportive studies. Study results showed that gumokimab delivered rapid and strong efficacy. The post China’s NMPA approves Akeso’s gumokimab for plaque psoriasis appeared first on Pharmaceutical Business review.
Coverage Details
Total News Sources36
Leaning Left6Leaning Right4Center11Last UpdatedBias Distribution52% Center
Bias Distribution
- 52% of the sources are Center
52% Center
L 29%
C 52%
R 19%
Factuality
To view factuality data please Upgrade to Premium
